Associated Genetic Biomarkers
ALK L1198F is present in 0.00% of AACR GENIE cases, with bile duct carcinoma having the greatest prevalence .
ALK L1198F serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains ALK L1198F as an inclusion criterion, 1 is phase 2 (1 open).
Trials with ALK L1198F in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma .
Crizotinib is the most frequent therapy in trials with ALK L1198F as an inclusion criteria .
Significance of ALK L1198F in Diseases
Non-Small Cell Lung Carcinoma +
ALK is mutated in 5.05% of non-small cell lung carcinoma patients .
ALK L1198F is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK L1198F and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
Crizotinib is the most frequent therapy in trials for non-small cell lung carcinoma that contain ALK L1198F .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.